Logo for MEI Pharma Inc

MEI Pharma Investor Relations Material

Latest events

Logo for MEI Pharma Inc

Q4 2023

MEI Pharma
Logo for MEI Pharma

Q1 2025

12 Nov, 2024
Logo for MEI Pharma

Q4 2024

18 Sep, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from MEI Pharma Inc

Access all reports
MEI Pharma Inc, formerly known as Marshall Edwards Inc., is a clinical-stage pharmaceutical company focusing on developing innovative therapies for cancer treatment. The company's drug development focus includes pracinostat, an oral histone deacetylase inhibitor aimed at treating advanced hematological diseases such as myelodysplastic syndrome. Additionally, MEI Pharma is working on ME-344, a mitochondrial inhibitor for the treatment of HER2-negative breast cancer and solid tumors, and Zandelisib (ME-401), an oral PI3K delta inhibitor for relapsed or refractory B-cell malignancies. Another key drug candidate is Voruciclib, an oral and selective cyclin-dependent kinase (CDK) inhibitor intended for the treatment of acute myeloid leukemia (AML) and B-cell malignancies, being developed in agreement with Presage. It is headquartered in San Diego, California, and its shares are listed on the Nasdaq.